Checkpoint Therapeutics Inc
0.0 %
39.22 %
Yet to be announced
Company Overview
Checkpoint Therapeutics, Inc. is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead product candidate is cosibelimab, an antibody that is in Phase 1 clinical trials in advanced cancers and a pivotal Phase 3 clinical trial for metastatic or locally advanced cutaneous squamous cell carcinoma.
Revenue Sources
The company is currently in research and development phase, with minimal revenue generation. Their primary focus is on developing cancer treatments, which is a halal business activity. Based on the financial data from the last four quarters, the company's revenue is primarily from research collaborations and grants, which are halal sources.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| June 30, 2024 | $41,000 | $6.71m | - | - | 0.00% | 0.00% |
| Dec. 31, 2023 | $6,000 | $10.18m | - | - | 0.00% | 0.00% |
Based on the financial data from the last four quarters, the company shows zero interest income and zero interest expense. Additionally, since the company is still in pre-revenue R&D phase, developing its pharmaceutical products, we skip the interest ratio calculations as per our methodology.
Operational Ethics
After reviewing the company's SEC filings, corporate documents, and public information, there is no evidence of any ongoing material associations with entities involved in human rights violations such as the state of Israel or the Chinese Communist Party.
Login to join the discussion